Printer Friendly
The Free Library
4,491,363 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Company Profile for Azaya Therapeutics, Inc.


Azaya Therapeutics is a biotechnology company that is developing the next generation of drug delivery technologies for the treatment of cancer. Its proprietary protein stabilizing liposomes (PSL PSL - Parallel Strand Lumber
PSL - parallel track single-unit long-range aid to navigation (LORAN) (US DoD)
PSL - Parti Social Libéral (French: Social Liberal Party)
PSL - Parts Selection List
PSL - Party for Socialism and Liberation
PSL - Passenger Service License
PSL - Path Signal Label
PSL - Path Switch LSR (Label Switched Router)
PSL - Peak Sidelobe Level
PSL - Percent of the Speed of Light (Andromeda)
) technology utilizes nanotechnology manufacturing processes to produce optimally sized liposomes for the targeted delivery of highly cytotoxic cyto·tox·ici·ty (-tk-ss drugs.
Company:                Azaya Therapeutics, Inc.

   Headquarters Address:   130 W. Rhapsody Drive
                           San Antonio, Texas 78216

   Main Telephone:         210-366-0006

   Type of Organization:   Private

   Industry:               Health: Biotechnology

   Key Executives:         President: Michael Dwyer

   All
     Contact:              Michael Dwyer
     Phone:                210-366-0006
     Email:                mdwyer@azaya.us

   Public Relations
     Contact:              Eric Whittington
     Phone:                210-227-0221, ext. 239
     Email:                ewhittington@dublinandassociates.com
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jun 10, 2005
Words:97
Previous Article:Company Profile for TelStrat.
Next Article:Company Profile for Thomas Technology Solutions, Inc.



Related Articles
EXONHIT INITIATES PHASE II CLINICAL TRIAL FOR EHT 0201.
Research and Markets: Cancer Pain, Which Is Caused By Tumor And Related Treatments - e.g., Chemotherapy, Radiation Therapy - Is Under-Treated...
Research and Markets: Growth In The Global Ophthalmic Disease Therapeutics Market Will Continue At A Compound Annual Growth Rate Of 11.9% To Reach...
Research and Markets: Thirteen Emerging Therapeutics Are Forecasted To Enter Osteoporosis Therapeutics Between 2004 And 2009.
Research and Markets: The Inflammatory Bowel Disorder Market Will Grow More Rapidly Than Previously Thought Due To The Introduction Of Additional...
Research and Markets: Drug Discovery Market Based on RNAi Projected to be $1 billion by 2010.
Weekly profile.(THE LABJ STOCK INDEX: TRACKING 200 SELECTED LOS ANGELES COUNTY-BASED COMPANIES)(AMGEN INC)(Brief Article)(Company Profile)
Azaya Therapeutics, Inc. Appoints Michael T. Dwyer as President, Chief Executive Officer and Director.
Azaya Therapeutics Patents Nanotherapy Breakthrough.
Azaya Therapeutics, Inc. Elects Ze'ev Shaked, Ph.D., to Board of Directors.

Terms of use | Copyright © 2008 Farlex, Inc. | Feedback | For webmasters | Submit articles